Scientists track cancer Drug's journey through the body
NCT ID NCT05109832
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 trial studied how healthy men absorb, process, and eliminate the experimental cancer drug IMP4297. Six Chinese male volunteers took a single radioactive-labeled dose so researchers could track the drug's path. The goal was to understand the drug's metabolism and excretion, not to test its effectiveness against tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMP4297 (a radioactive-labeled drug being studied for solid tumors)
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China